A Phase Ib Study of Indirect Immunization with Oregovomab and Toll-like-Receptor-3 Stimulation with Hiltonol

Robert W Holloway, Sarah M Temkin, Sarah W Gordon, Sunil Gupta, Srinivasa R Jada, Sarfraz Ahmad, William P McGuire

Abstract readClinical Trial, Phase I

In one paragraph

Article in Current oncology (Toronto, Ont.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Robert W HollowayGynecologic Oncology Program, AdventHealth Cancer Institute, Orlando, FL 32804, USA.ORCID 0000-0002-3121-4605

Sarah M TemkinDivision of Gynecologic Oncology, Virginia Commonwealth University, Richmond, VA 23298, USA.ORCID 0000-0002-6472-2745

Sarah W GordonDivision of Gynecologic Oncology, Virginia Commonwealth University, Richmond, VA 23298, USA.ORCID 0000-0003-0443-5573

Sunil GuptaCanariaBio, Inc., Seoul 06044, Gyeonggi-do, Republic of Korea.

Srinivasa R JadaCanariaBio, Inc., Seoul 06044, Gyeonggi-do, Republic of Korea.

Sarfraz AhmadGynecologic Oncology Program, AdventHealth Cancer Institute, Orlando, FL 32804, USA.ORCID 0000-0002-5180-0409

William P McGuireDivision of Gynecologic Oncology, Virginia Commonwealth University, Richmond, VA 23298, USA.

Funding

OncoQuest Pharmaceuticals, Inc. Edmonton, AB, Canada. xx

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Neoplasm Recurrence, LocalOvarian NeoplasmsPoly I-CPolylysineToll-Like Receptor 3Adjuvants, ImmunologicAdultAgedCarboxymethylcellulose SodiumDrug Resistance, NeoplasmFemaleHumansMiddle AgedAdjuvants, ImmunologicCarboxymethylcellulose SodiumPoly I-Cpoly ICLCPolylysineTLR3 protein, humanToll-Like Receptor 3CA-125Hiltonol®indirect immunizationoregovomabovarian cancerphase Ib studyplatinum-resistancerecurrent diseasesurvival analysisTLR3 stimulation

Identifiers

PMID41149451

DOI10.3390/curroncol32100532

PMCPMC12564844

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.